Medical device innovation firm TheraNova said this week it is partnering with incubator-accelerator UCSF Surgical Innovations to help co-develop device tech intended to address unmet patient needs.
The partnership will establish collaboration between both sites, allowing parties to utilize UCSF’s intellectual and clinical environment and TheraNova’s product development capabilities and knowledge, the San Francisco-based companies said.
“As industry director of the UC Berkeley-UCSF Master of Translational Medicine program I have been impressed with the caliber of both the students and the faculty. With this official partnership with Surgical Innovations, we are hoping to work more closely with UCSF innovators to bring more impactful products to market,” TheraNova CEO Dr. Dan Burnett said in a prepared statement.
TheraNova said it is hopeful that its projects and spinouts will be able to benefit from UCSF expertise and collaborators for clinical trials and academic grants. UCSF tech will also be supported by TheraNova and its certified manufacturing facilities, product development and fundraising knowledge.
“As a major source of medtech innovation in San Francisco, UCSF has an unparalleled environment for device invention at the doorstep of Silicon Valley. We have world-class clinical KOLs, state-of-the-art research facilities, leading translational bioengineers and passionate trainees working at the frontier of patient care,” UCSF Surgical Innovations clinical lead Dr. Hanmin Lee of UCSF Benioff Children’s Hospital said in a press release.
“UCSF has a long history of collaborating with external partners to translate our research into actual products. TheraNova has resources in every step of the device development process, and we look forward to utilizing their expertise and working together to accelerate groundbreaking innovation to patients,” Shuvo Roy of UCSF said in a prepared release.
